CTS 21166

Drug Profile

CTS 21166

Alternative Names: ATG-Z1; CTS-21166; ZPQ 21166

Latest Information Update: 21 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CoMentis
  • Class Nootropics; Small molecules
  • Mechanism of Action Amyloid precursor protein secretase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Alzheimer's disease

Most Recent Events

  • 21 Apr 2016 No recent reports on development identified - Phase-I for Alzheimer's disease in USA (IV)
  • 16 Oct 2014 Astellas Pharma exercises option to terminate its collaboration agreement with CoMentis
  • 25 Apr 2008 Astellas Pharma and CoMentis have entered into an exclusive collaboration agreement to develop and commercialise CTS 21166 worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top